This is what a buyout is all about. ITMN has $40MM in sales and a blockbuster on the way. At $8.6B, this translates to about a $40pps for ARIA. The only thing Ariad needs is drug that has the same PROVEN potential as Pirfenidone. Right now Pona is at the unproven potential stage. Maybe with the AE reduction protocols and trials in 3-4 years, we get there, or maybe if mN is a winner. '113 getting a boost with the PFE troubles.